Published in Adv Immunol on January 01, 1973
TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. N Engl J Med (2007) 12.24
Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther (2005) 3.17
A spontaneous rheumatoid arthritis-like disease in MRL/l mice. J Exp Med (1982) 2.76
Lymphocytes transformed by Epstein-Barr virus. Induction of nuclear antigen reactive with antibody in rheumatoid arthritis. J Exp Med (1978) 2.52
Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A (1996) 2.36
Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes. J Clin Invest (1977) 2.07
Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci U S A (1982) 1.99
Arthritogenic monoclonal antibodies from K/BxN mice. J Exp Med (2002) 1.94
Inhibition of antigen- and mitogen-induced human lymphocyte proliferation by gold compounds. J Clin Invest (1977) 1.89
Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci U S A (2007) 1.84
Histochemical discrimination of HLA-DR positive cell populations in the normal and arthritic synovial lining. Clin Exp Immunol (1982) 1.75
Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A (1989) 1.72
Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood (2002) 1.64
Cryoimmunoglobulinemia in rheumatoid arthritis. Significance in serum of patients with rheumatoid vasculitis. J Clin Invest (1975) 1.62
Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther (2008) 1.62
Induction of monocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice. J Exp Med (1981) 1.62
The involvement of interdigitating (antigen-presenting) cells in the pathogenesis of rheumatoid arthritis. Clin Exp Immunol (1983) 1.56
Antibody to streptococcal cell wall peptidoglycan-polysaccharide polymers in seropositive and seronegative rheumatic disease. Clin Exp Immunol (1984) 1.50
Complete sequence of the genes encoding the VH and VL regions of low- and high-affinity monoclonal IgM and IgA1 rheumatoid factors produced by CD5+ B cells from a rheumatoid arthritis patient. Int Immunol (1991) 1.50
Immunoglobulin phagocytosis by granulocytes from sera and synovial fluids in various rheumatoid and nonrheumatoid diseases. Ann Rheum Dis (1975) 1.50
Isolation and analysis of complement activating aggregates from synovial fluid of patients with rheumatoid arthritis using monoclonal anti-C3d antibodies. Ann Rheum Dis (1987) 1.49
Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest (1989) 1.36
Genetic analysis of self-associating immunoglobulin G rheumatoid factors from two rheumatoid synovia implicates an antigen-driven response. J Exp Med (1992) 1.32
Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest (2001) 1.30
Increased production and expression of tissue thromboplastin-like procoagulant activity in vitro by allogeneically stimulated human leukocytes. J Clin Invest (1978) 1.28
Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis (2006) 1.27
Inhibition of human endothelial cell proliferation by gold compounds. J Clin Invest (1987) 1.22
Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med (1997) 1.18
B cells in rheumatoid arthritis. Arthritis Res (2000) 1.18
The inflammatory role of immune complexes trapped in joint collagenous tissues. Clin Exp Immunol (1978) 1.18
Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis. Arthritis Res Ther (2010) 1.16
Inhibition of human helper T cell function in vitro by D-penicillamine and CuSO4. J Clin Invest (1980) 1.13
Clinical application of a new nephelometric technique to measure complement activation. J Clin Pathol (1983) 1.13
Characterization of histopathology and gene-expression profiles of synovitis in early rheumatoid arthritis using targeted biopsy specimens. Arthritis Res Ther (2005) 1.13
Immune complex detection and complement activity in rheumatoid arthritis: a comparative study of a radioimmunoassay using monoclonal rheumatoid factor, gel diffusion techniques and C4 activity. Clin Exp Immunol (1978) 1.12
Rat arthritis due to whole group B streptococci. Clinical and histopathologic features compared with groups A and D. Am J Pathol (1983) 1.11
Localization of a critical restriction site on the I-A beta chain that determines susceptibility to collagen-induced arthritis in mice. Proc Natl Acad Sci U S A (1989) 1.10
Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol (2009) 1.09
Monocyte migration to arthritis in the rat utilizes both CD11/CD18 and very late activation antigen 4 integrin mechanisms. J Exp Med (1995) 1.08
Immune complexes in early arthritis. II. Immune complex constituents are synthesized in the synovium before rheumatoid factors. Clin Exp Immunol (1982) 1.07
Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. Clin Exp Immunol (2005) 1.06
Serum immune complexes containing IgA appear to predict erosive arthritis in a longitudinal study in rheumatoid arthritis. Ann Rheum Dis (1986) 1.06
Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper- or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes. J Clin Invest (1984) 1.06
Rheumatoid factor plaque-forming cells in rheumatoid synovial tissue. Clin Exp Immunol (1977) 1.05
Immune complexes in human diseases: a review. Am J Pathol (1980) 1.05
Chronic arthritis associated with the presence of intrasynovial rubella virus. Ann Rheum Dis (1983) 1.04
Detection of immune complexes in acute rheumatic fever and their relationship to HLA-B5. J Clin Invest (1980) 1.03
A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? Arthritis Res (2000) 1.03
Lymphoid abnormalities in rats with adjuvant-induced arthritis. I. Mitogen responsiveness and lymphokine synthesis. Ann Rheum Dis (1984) 1.03
Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis. J Exp Med (2003) 1.03
Increased FcgammaRII expression and aberrant tumour necrosis factor alpha production by mature dendritic cells from patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 1.02
Rubella virus and rheumatoid arthritis. Ann Rheum Dis (1977) 1.01
Lymphocytes in rheumatoid and nonrheumatoid synovial fluids. Nonspecificity of high T-cell and low B-cell percentages. Ann Rheum Dis (1975) 1.00
Clinical application of new technique that measures C4d for assessment of activation of classical complement pathway. J Clin Pathol (1988) 1.00
Effects of acetylsalicylic acid on normal human peripheral blood lymphocytes. Inhibition of mitogen- and antigen-stimulated incorporation of tritiated thymidine. Clin Exp Immunol (1976) 1.00
Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints. Arthritis Res Ther (2010) 0.99
Does rheumatoid arthritis have a clinicopathological spectrum similar to that of leprosy? Ann Rheum Dis (1982) 0.98
The role of IgM rheumatoid factor in experimental immune vasculitis. Clin Exp Immunol (1979) 0.98
Membrane characteristics of adherent cells dissociated from rheumatoid synovial tissue. Clin Exp Immunol (1977) 0.97
Mac-1 (CD11b/CD18) is the predominant beta 2 (CD18) integrin mediating human neutrophil migration through synovial and dermal fibroblast barriers. Immunology (1996) 0.97
A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients. Clin Exp Immunol (1986) 0.96
A study of complement fixation by rheumatoid factor using a haemolytic assay system. Clin Exp Immunol (1977) 0.96
Idiotypic network: possible explanation of seronegativity in a patient with rheumatoid arthritis. Clin Exp Immunol (1984) 0.95
Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal? J Clin Pathol (1989) 0.95
A new model for rheumatoid arthritis? Arthritis Res (2000) 0.93
Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J Clin Invest (1985) 0.93
Protease inhibitors in inflammatory synovial effusions. Ann Rheum Dis (1981) 0.93
Analysis of in vitro polyclonal B cell differentiation responses to bacterial peptidoglycan and pokeweed mitogen in rheumatoid arthritis. Clin Exp Immunol (1984) 0.92
The binding affinities of rheumatoid factors interacting with the C gamma 3 homology region of human IgG. Clin Exp Immunol (1973) 0.92
Detection of immune complexes and their relationship to rheumatoid factor in a variety of autoimmune disorders. Clin Exp Immunol (1981) 0.92
Oxygen free-radicals mediate an inhibition of proteoglycan synthesis in cultured articular cartilage. Ann Rheum Dis (1984) 0.91
Interaction in vitro between synovial cells and autologous lymphocytes and sera from arthritis patients. J Clin Pathol (1975) 0.91
The role and clinical implications of G6PI in experimental models of rheumatoid arthritis. Arthritis Res Ther (2004) 0.90
Immunoblasts in synovial fluid and blood in the rheumatic diseases. Ann Rheum Dis (1980) 0.87
Synovial protease/inhibitor ratios in erosive and nonerosive arthropathies. Ann Rheum Dis (1984) 0.87
Immunopathological changes in rheumatoid arthritis and other joint diseases. J Clin Pathol (1975) 0.87
Systemic administration of tolerogenic dendritic cells ameliorates murine inflammatory arthritis. Open Rheumatol J (2008) 0.87
Rheumatoid factors: clinical applications. Dis Markers (2013) 0.87
Conditioned medium from stimulated mononuclear leucocytes potentiates the ability of human neutrophils to damage human articular cartilage. Ann Rheum Dis (1988) 0.86
Role of cytological analysis of synovial fluid in diagnosis and research. Ann Rheum Dis (1991) 0.86
Analysis of immunoglobulins secreted by hybridomas derived from rheumatoid synovia. Clin Exp Immunol (1990) 0.86
Neutrophil expression of tumour necrosis factor receptors (TNF-R) and of activation markers (CD11b, CD43, CD63) in rheumatoid arthritis. Clin Exp Immunol (1995) 0.86
Clonally-related immunoglobulin VH domains and nonrandom use of DH gene segments in rheumatoid arthritis synovium. Mol Med (1998) 0.86
Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice. Arthritis Rheum (2011) 0.85
Tissue C3b receptors. Clin Exp Immunol (1979) 0.84
Effect of penicillamine on complement in vitro and in vivo. Ann Rheum Dis (1977) 0.83
Inflammatory synovial tissue mononuclear cells release leucocyte migration inhibition factor in antigen- and mitogen-free cultures. Ann Rheum Dis (1981) 0.83
Specific accumulation of technetium-99m radiolabelled, negative liposomes in the inflamed paws of rats with adjuvant induced arthritis: effect of liposome size. Ann Rheum Dis (1989) 0.83
Macrophage-lymphocyte clustering in rheumatoid arthritis. Ann Rheum Dis (1975) 0.83
Kallikreins and kinins: mediators in inflammatory joint disease? Int J Exp Pathol (1990) 0.82
Significance of connective tissue proliferation in the breakdown of cartilage: a novel in vivo model. Ann Rheum Dis (1986) 0.82
VH usage and somatic hypermutation in peripheral blood B cells of patients with rheumatoid arthritis (RA). Clin Exp Immunol (1998) 0.82
Deposits of alpha 2M in the rheumatoid synovial membrane. Ann Rheum Dis (1982) 0.81
Immunoglobulin heavy chain variable region gene utilization by B cell hybridomas derived from rheumatoid synovial tissue. Clin Exp Immunol (1992) 0.81
The stabilizing effect of synovectomy on the synovial membrane in arthritic rabbit knees. Arch Orthop Trauma Surg (1986) 0.81
Rapid single-step method for purification of polymorphonuclear leucocytes from blood of patients with rheumatoid arthritis. Clin Exp Immunol (1982) 0.81
Immunochemical quantitation of complement components of Clq and C3 in sera and synovial fluids of patients with bone and joint diseases. Ann Rheum Dis (1980) 0.81
Protective autoantibodies in the rheumatic diseases: lessons for therapy. Nat Rev Rheumatol (2013) 0.81
Complement activating properties of monoreactive and polyreactive IgM rheumatoid factors. Ann Rheum Dis (1993) 0.81
The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum (1990) 5.09
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood (2000) 4.18
How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum (1990) 3.78
Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore) (1980) 3.20
Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A (1997) 2.80
Unusual synovial fluid findings in Reiter's syndrome. Ann Intern Med (1967) 2.47
Apoptosis in rheumatoid arthritis synovium. J Clin Invest (1995) 2.39
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
Breakdown products of C 3 in human synovial fluids. J Clin Invest (1969) 2.31
Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest (1976) 2.20
Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest (1989) 2.18
Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J Immunol (1992) 2.08
Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor. Arthritis Rheum (1987) 2.04
Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol Today (2000) 2.03
Rabbit anaphylactic antibody. J Exp Med (1966) 2.01
Reactions of aggregated mercaptoethanol treated gamma globulin with rheumatoid factor--precipitin and complement fixation studies. Arthritis Rheum (1968) 1.88
Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol (1996) 1.65
Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest (1996) 1.65
Rheumatoid synovitis. An extravascular immune complex disease. Arthritis Rheum (1974) 1.59
Epstein-Barr virus. Its relationship to the pathogenesis of rheumatoid arthritis. Arthritis Rheum (1981) 1.53
Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum (1997) 1.52
Antigen induced histamine release from platelets of rabbits producing homologous PCA antibody. Proc Soc Exp Biol Med (1966) 1.51
Identification of immunostimulatory dendritic cells in the synovial effusions of patients with rheumatoid arthritis. J Clin Invest (1985) 1.47
Impaired regulation of Epstein-Barr virus-induced lymphocyte proliferation in rheumatoid arthritis is due to a T cell defect. J Immunol (1981) 1.44
Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum (2002) 1.38
Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus. Clin Exp Immunol (1972) 1.36
Quantitative phagocytosis by neutrophils. I. A new method with immune complexes. J Immunol (1973) 1.36
p53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis. Arthritis Rheum (1999) 1.35
Altered regulation of Epstein-Barr virus induced lymphoblast proliferation in rheumatoid arthritis lymphoid cells. Arthritis Rheum (1980) 1.31
Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest (2001) 1.30
Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum (1994) 1.26
Rabbit homocytotropic antibody. A unique rabbit immunoglobulin analogous to human IgE. J Exp Med (1969) 1.26
Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. Am J Pathol (1998) 1.26
In vivo synthesis of IgG by rheumatoid synovium. J Lab Clin Med (1970) 1.24
Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondritis and Behçet's disease. Am J Med (1985) 1.22
IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol (1992) 1.22
Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. Arthritis Rheum (2000) 1.22
Native DNA binding in rheumatoid arthritis. Ann Rheum Dis (1974) 1.20
Wrist arthropathy in calcium pyrophosphate dihydrate deposition disease. Arthritis Rheum (1976) 1.17
Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. I. A cytofluorographic study of monocyte differentiation antigens and class II antigens and their regulation by gamma-interferon. Arthritis Rheum (1987) 1.14
Down regulation of human monocyte differentiation antigens by interferon gamma. Cell Immunol (1987) 1.13
Antinuclear factors and chronic articular inflammation. Clin Exp Immunol (1971) 1.11
Lymphocyte alteration by procainamide: relation to drug-induced lupus erythematosus syndrome. Lancet (1979) 1.10
Further speculation on the pathogenesis of joint inflammation in rheumatoid arthritis. Arthritis Rheum (1971) 1.09
Cellular immunity in the joints of patients with rheumatoid arthritis and other forms of chronic synovitis. Rheum Dis Clin North Am (1987) 1.09
Quantitative phagocytosis by neutrophils. II. Release of the C5-cleaving enzyme and inhibition of phagocytosis by rheumatoid factor. J Immunol (1973) 1.08
Studies of rheumatoid synovial fluid lymphocytes. II. A comparison of their behavior with blood mononuclear cells in the autologous mixed lymphocyte reaction and response to TCGF. Clin Immunol Immunopathol (1983) 1.08
The removal of aggregated and nonaggregated autologous gamma globulin from rheumatoid joints. Arthritis Rheum (1969) 1.08
Concurrent intrathoracic Hodgkin's disease and hypertrophic osteoarthropathy. Chest (1973) 1.08
The pathogenesis of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum (1982) 1.06
Transforming growth factor-beta 1 selectively inhibits IL-3-dependent mast cell proliferation without affecting mast cell function or differentiation. J Immunol (1989) 1.05
Immunologic effects of cyclophosphamide treatment in rheumatoid arthritis. Arthritis Rheum (1971) 1.04
Characterization of the killer cell generated in the autologous mixed leukocyte reaction. J Exp Med (1983) 1.02
Studies of rheumatoid synovial fluid lymphocytes. I. Evidence for activated natural killer- (NK) like cells. J Immunol (1982) 1.01
Cytology of synovial fluid in rheumatoid arthritis. Am J Clin Pathol (1967) 0.99
Antinuclear antibodies and nuclear antigens in rheumatoid synovial fluids. Clin Immunol Immunopathol (1973) 0.98
Selective production of human antigen specific helper factor from normal volunteers: implications for human Ir genes. Clin Exp Immunol (1979) 0.97
Characterization of the natural killer-like lymphocytes in rheumatoid synovial fluid. J Immunol (1985) 0.95
Calcium pyrophosphate dihydrate deposition disease without chondrocalcinosis. J Rheumatol (1975) 0.95
Lupus cystitis: primary bladder manifestations of systemic lupus erythematosus. Ann Intern Med (1983) 0.92
Anticytokine therapy in rheumatoid arthritis. N Engl J Med (1997) 0.92
Rheumatoid factor and the fixation of complement. Ann N Y Acad Sci (1969) 0.91
Immunoreactants in rheumatoid synovial effusions. J Exp Med (1971) 0.91
Serologic studies in a family with heterozygous C2 deficiency. Am J Med (1981) 0.90
Lymphocytotoxic antibody activity in cryoprecipitates from serum of patients with SLE. Arthritis Rheum (1976) 0.89
Antimalarial treatment of rheumatoid arthritis. Med Clin North Am (1968) 0.89
Lymphocyte reactivity of antisera to cryoproteins in systemic lupus erythematosus. Clin Immunol Immunopathol (1979) 0.87
Alterations in immune responsiveness in women exposed to diethylstilbestrol in utero. Fertil Steril (1987) 0.87
Interrelationship of rheumatoid arthritis, folic acid, and aspirin. Blood (1971) 0.87
Granulomatous angiitis of the nervous system: case report and review of the literature. Arthritis Rheum (1982) 0.87
Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on fibroblast-like synoviocytes: paradoxical induction of IFN-gamma and TNF-alpha receptor expression. J Clin Immunol (1993) 0.86
The association of antinuclear antibodies, antilymphocyte antibodies, and C4 activation among the relatives of children with systemic lupus erythematosus. Arthritis Rheum (1982) 0.85
Reactive arthritis. Annu Rev Med (1987) 0.85
Rheumatoid arthritis. The multiple pathways to chronic synovitis. Lab Invest (1995) 0.85
Factors influencing the production of early, heat labile, rabbit anaphylactic antibody. J Immunol (1969) 0.83
Pathogenesis of the joint disease of rheumatoid arthritis. Am J Med (1983) 0.83
An office technique for identifying crystal in synovial fluid. Am Fam Physician (1975) 0.83
The role of T cells in rheumatoid arthritis. Ann Rheum Dis (1993) 0.82
The clinical significance of deoxyribonucleic acid particles in synovial fluid. Ann Intern Med (1966) 0.82
Echocardiographic assessment of cardiac structure and function in patients with rheumatoid arthritis. Am J Med (1977) 0.82
Impaired killer cell generation in the autologous mixed leukocyte reaction by rheumatoid arthritis lymphocytes. Arthritis Rheum (1985) 0.82
Characterization of the precursors of the NK-like cytotoxic cells generated in the autologous mixed leukocyte reaction and by interleukin 2 activation. J Clin Lab Immunol (1986) 0.82
The pathogenesis of rheumatoid arthritis. A critical assessment of the role of autologous stimulation in the perpetuation of rheumatoid synovitis. Rheum Dis Clin North Am (1987) 0.81
Generation of human cytomegalovirus-specific cytotoxic T-lymphocytes in a short-term culture. J Immunol Methods (1988) 0.81
The role of xenoantigen in the human autologous mixed lymphocyte reaction: ability to respond in the absence of exposure to xenoantigen depends on the method of T-cell preparation. Clin Immunol Immunopathol (1985) 0.81
High percentage of CD8+, Leu-7+ cells in rheumatoid arthritis synovial fluid. Arthritis Rheum (1992) 0.81
C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus. Clin Exp Immunol (1976) 0.81
Human and mouse specific T-cell helper factors assayed in vivo and in vitro: implications for human Ir genes. Transplant Proc (1979) 0.81
Procainamide-lymphocyte reactions. A possible explanation for drug-induced autoimmunity. Arthritis Rheum (1981) 0.81
Alteration of rabbit PCA reaction by drugs known to influence intracellular cyclic AMP. J Immunol (1974) 0.80
Antibodies reactive with central nervous system antigens. Hum Pathol (1983) 0.80
Rheumatoid arthritis. Dis Mon (1974) 0.80
Antibody-mediated suppression of antibody-dependent cytotoxic effector cell function. Clin Immunol Immunopathol (1979) 0.80